# Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease

> **NCT01018875** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 242 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** ABT-288
- **DRUG:** donepezil
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01018875
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 242 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01018875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01018875, "Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01018875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*